论文部分内容阅读
小干扰RNA(small interfering RNAs,siRNAs)是近年来靶向治疗人类乳头瘤病毒(human papillomavirus,HPV)的分子生物学研究热点。该技术在抗HPV的靶向性研究中具有高特异性、放大效应、作用稳定、并可遗传等特征,为宫颈癌防治中抗HPV基因治疗提供了新途径。但siRNAs技术研发的核酸药物应用于临床仍面临者许多挑战和尚未解决的问题。今后抗HPV治疗的发展方向和研究重点仍将是采用siRNA技术在HPV相应位点阻断病毒复制,联合抗病毒的全身免疫调节的综合治疗以提高疗效。
Small interfering RNAs (siRNAs) have been the focus of molecular biology in recent years for targeting human papillomavirus (HPV). The technology has high specificity, amplification effect, stable effect and inherited characteristics in the anti-HPV targeted study, which provides a new way for anti-HPV gene therapy in the prevention and treatment of cervical cancer. However, the nucleic acid drugs developed by siRNAs technology still face many challenges and unresolved problems in clinical application. Future development of anti-HPV treatment and research focus will continue to use siRNA technology in the corresponding sites of HPV block virus replication, combined with antiviral systemic immunomodulatory treatment to improve efficacy.